Bhindi Bimal, Carlson Rachel E, Mason Ross J, Schulte Phillip J, Gettman Matthew T, Frank Igor, Tollefson Matthew K, Thompson R Houston, Boorjian Stephen A, Leibovich Bradley C, Karnes R Jeffrey
Department of Urology, Mayo Clinic, Rochester, MN.
Department of Biostatistics, Mayo Clinic, Rochester, MN.
Urology. 2017 Nov;109:145-152. doi: 10.1016/j.urology.2017.06.054. Epub 2017 Aug 18.
To evaluate if adjuvant radiation therapy (ART) is associated with improved long-term oncologic outcomes for pT2N0R1 prostate cancer (PCa).
Men with pT2N0 PCa and a single positive surgical margin following radical prostatectomy and pelvic lymphadenectomy were identified (1987-1996). Men who received ART were matched 1:1 to men who did not receive ART based on age, year of surgery, Gleason score, preoperative prostate-specific antigen, site of positive surgical margin, and DNA ploidy. Biochemical recurrence (BCR), local recurrence, distant metastasis, and overall survival (OS) were compared between groups in time-to-event analyses.
The cohort included 152 men (76 per group) with a median follow-up of 20 years (interquartile range 19,22). ART was associated with a lower cumulative incidence of BCR (25% vs 52%; P <.001) and local recurrence (3% vs 12%; P = .03), but no significant differences in cumulative incidence of distant metastasis (10% vs 7%; P = .44) or in probability of OS (56% vs 68%; P = .08) at 20 years. In competing risks models, receipt of ART was associated with reduced risks of BCR (hazard ratio [HR] = 0.40; 95% confidence interval [CI] 0.23-0.70; P <.001) and local recurrence (HR = 0.21; 95% CI .05-0.98; P = .05), but not distant metastasis (HR = 1.56; 95% CI 0.51-4.75; P = .43). In the Cox model, ART was not associated with improved OS (HR = 1.56; 95% CI 0.94-2.57; P = .08).
ART was associated with reduced risks of BCR and local recurrence for men with pT2N0R1 PCa. However, ART was not significantly associated with metastasis-free or OS benefits, as recurrences in these patients generally followed an indolent trajectory with 20 years of median follow-up.
评估辅助放疗(ART)是否与pT2N0R1期前列腺癌(PCa)患者长期肿瘤学结局的改善相关。
纳入1987 - 1996年间接受根治性前列腺切除术和盆腔淋巴结清扫术后病理分期为pT2N0且手术切缘单阳性的男性患者。根据年龄、手术年份、Gleason评分、术前前列腺特异性抗原、手术切缘阳性部位和DNA倍体,将接受ART的患者与未接受ART的患者按1:1进行匹配。在事件发生时间分析中比较两组间的生化复发(BCR)、局部复发、远处转移和总生存(OS)情况。
该队列包括152名男性(每组76名),中位随访时间为20年(四分位间距19,22)。ART与较低的BCR累积发生率(25%对52%;P <.001)和局部复发率(3%对12%;P =.03)相关,但在20年时远处转移累积发生率(10%对7%;P =.44)或OS概率(56%对68%;P =.08)方面无显著差异。在竞争风险模型中,接受ART与BCR风险降低(风险比[HR] = 0.40;95%置信区间[CI] 0.23 - 0.70;P <.001)和局部复发风险降低(HR = 0.21;95% CI.05 - 0.98;P =.05)相关,但与远处转移无关(HR = 1.56;95% CI 0.51 - 4.75;P =.43)。在Cox模型中,ART与OS改善无关(HR = 1.56;95% CI 0.94 - 2.57;P =.08)。
对于pT2N0R1期PCa男性患者,ART与BCR和局部复发风险降低相关。然而,ART与无转移或OS获益无显著关联,因为这些患者的复发通常呈惰性病程,中位随访时间为20年。